CX3CR1 and neoplasm: The authors suggested that profiling T cells expressing CX3CR1 in peripheral blood not only identifies patients with improved clinical benefit, but also serves as a dynamic marker to identify T cell repertoires that are reflective of tumor-infiltrating lymphocytes.